Drug Database
Back to search

Netherlands· NL-938e0c213774

Besremi 250 microgram/0,5 ml oplossing voor injectie in een voorgevulde pen

A ropeginterferon alfa-2b product containing ropeginterferon alfa-2b, registered in Netherlands by AOP Orphan Pharmaceuticals AG. The same ATC class is registered in 12 of our 19 countries.

ATC L03AB15

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBesremi 250 microgram/0,5 ml oplossin…ATCL03AB15REGISTER NO.NL-938e0c213774PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ropeginterferon alfa-2bAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ropeginterferon alfa-2b is registered in 12 of 19 countries.

Countries holding a registration under ATC L03AB15 (ropeginterferon alfa-2b), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search ropeginterferon alfa-2b products by name

Ropeginterferon alfa-2b · ATC L03AB15

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ROPEGINTERFERON ALFA-2B
Manufacturer
AOP Orphan Pharmaceuticals AG
Country
Netherlands (NL)
ATC code
L03AB15
ATC class
Ropeginterferon alfa-2b
Defined daily dose
18 mcg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1352

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ropeginterferon alfa-2b in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ropeginterferon alfa-2b products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Besremi
  • Liechtenstein · Besremi
  • Norway · Besremi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8e9a194d-935f-4e15-8cc5-6c9fe081ca03
GET /v1/drugs/8e9a194d-935f-4e15-8cc5-6c9fe081ca03?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/besremi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ropeginterferon alfa-2b",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp120679",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "BENZYLALCOHOL (E 1519)",
    "NATRIUMACETAAT 0-WATER (E 262)",
    "NATRIUMCHLORIDE",
    "POLYSORBAAT 80 (E 433)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "ROPEGINTERFERON ALFA-2B"
  ],
  "leaflet_url": null,
  "authorised_at": "2019/02/15",
  "procedure_number": "EMEA/H/C/004128",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1352",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about ropeginterferon alfa-2b.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console